EGFR and laryngotracheoesophageal cleft: Moreover, of the 83 inhibitors, 20 are already in use for the treatment of LC in patients with ALK, BRAF, EGFR, ERBB2, MEK, MET, NTRK2 and RET alterations.11, 40